Can Congress Speed Up CBD Regulation?

Experts weigh in on the various legislative pathways WASHINGTON — Having already submitted two congressionally mandated reports on cannabidiol (CBD), it’s looking less and less likely that the U.S. Food and Drug Administration (FDA) will release the long-awaited regulations that would provide a pathway for ingestible products. Leaving many in the industry to question if Congress

By |2020-09-14T08:43:17-06:00September 14th, 2020|HLG In The News|

Struggling Economy Might Signal Time For Cannabis Businesses To Seek Out Real Estate Deals

The COVID-19 crisis and ensuing economic downturn have created opportunities for cannabis companies to finagle deals on real estate belonging to mainstream businesses or marijuana firms that are scaling back or even closing their doors. Other cannabis companies are simply hoping their landlords will lower rents to fill vacant properties or to avoid losing existing

By |2020-08-17T09:44:22-06:00August 17th, 2020|HLG In The News|

The Hoban Minute – 99 | Shake Brands’ Antigone Davoulas & Julie Brents | Celebrating the Badass Women of Cannabis

The Hoban Minute - 99 | Shake Brands’ Antigone Davoulas & Julie Brents | Celebrating the Badass Women of Cannabis Bob, Eric, and Halston sit down with the COO and Chief Legal Officer, Antigone Davoulas and Julie Brents to discuss the importance of supporting women through the cannabis supply chain, being awarded the first processing

By |2020-08-11T10:13:31-06:00August 11th, 2020|The Hoban Minute|

4 Takeaways From the FDA’s CBD Accuracy Report

Multiyear studies show the industry is improving but could be better WASHINGTON — The U.S. Food and Drug Administration (FDA) submitted a report to Congress in July outlining numerous studies the agency has conducted to determine the labeling accuracy of various cannabidiol (CBD) products. As covered by Marijuana Moment, the report was the second mandated

By |2020-09-09T10:33:27-06:00August 10th, 2020|HLG In The News|

The CBD “Industry” Is Here To Stay

Written By: Robert Hoban Hemp legalization has solidified that products containing cannabidiol (CBD) aren’t going away. Last February, Stephen Hahn, Commissioner of the Food and Drug Administration (FDA), acknowledged that it was “a fool's game” to attempt to pull hemp-derived CBD products off the market. This echoes the sentiment of former interim Commissioner, Scott Gottlieb, who’d

By |2020-08-03T08:43:11-06:00August 3rd, 2020|HLG In The News|

As Maryland’s Medical Marijuana Market Ascends, Diversity Issues Linger

The medical cannabis market in Maryland is flourishing, with sales rapidly moving toward half a billion dollars a year. Experts credit that success, in part, to clear and transparent regulations – and regulators who have balanced compliance with patient access. But a huge lingering issue looms: litigation and investigations into a 2019 licensing round that

By |2020-07-27T12:55:30-06:00July 27th, 2020|HLG In The News|
Go to Top